A. Di Marco
YOU?
Author Swipe
View article: Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study Open
Background Immune checkpoint inhibitor doublet (ICI–ICI) and ICI plus tyrosine kinase inhibitor (ICI–TKI) regimens are the cornerstone of treatment for metastatic renal cell carcinoma (mRCC), although no head-to-head comparisons are curren…
View article: Skin metastasis of BRCA mutated prostate cancer: A case report and a brief review of literature
Skin metastasis of BRCA mutated prostate cancer: A case report and a brief review of literature Open
Rationale: Metastatic castration-resistant prostate cancer has a poor prognosis especially when harboring DNA damage repair gene mutations, nevertheless, in the case of pathogenic BRCA gene mutations, PARPi demonstrated a survival benefit …
View article: Multiorgan failure caused by pembrolizumab and axitinib in a woman affected by metastatic clear cell renal cell carcinoma: A case report and literature review
Multiorgan failure caused by pembrolizumab and axitinib in a woman affected by metastatic clear cell renal cell carcinoma: A case report and literature review Open
Rationale: Treatment with a combination of immune checkpoint inhibitors (ICIs) (pembrolizumab or nivolumab) and oral Tyrosine Kinase Inhibitors (TKI) targeting angiogenesis (axitinib, cabozantinib or lenvatinib) has shown benefits in terms…
View article: Correction to: Surgery in reference centers improves survival of sarcoma patients: a nationwide study
Correction to: Surgery in reference centers improves survival of sarcoma patients: a nationwide study Open
View article: Surgery in reference centers improves survival of sarcoma patients: a nationwide study
Surgery in reference centers improves survival of sarcoma patients: a nationwide study Open
View article: Primary small cell carcinoma of the larynx. Survival time of 47 months. Case report
Primary small cell carcinoma of the larynx. Survival time of 47 months. Case report Open
Small cell carcinoma (SCC) of the larynx is a rare type of neuroendocrine carcinoma (NEC), few cases of which have been described in the literature. The prognosis for this type of carcinoma is poor, with a survival time typically not excee…